drugset / Trial / NCT04381091

Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study

NCT04381091 ↗

Expanded access No longer available Santhera Pharmaceuticals

Summary

Expanded Access Program for Idebenone in Patients with Leber's Hereditary Optic Neuropathy who completed the LEROS Study

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Background Idebenone Small molecule 900 mg Oral